X4 Pharmaceuticals, Inc. (XFOR) 10-Year Financial Performance & Capital Metrics

XFOR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.Show more

Revenue $3M
EBITDA -$36M +66.8%
Net Income -$37M +63.0%
EPS (Diluted) -5.59 +67.3%
Gross Margin 68.83%
EBITDA Margin -1392.45%
Operating Margin -1423.58%
Net Margin -1464.61%
ROE -102.26% +36.8%
ROIC -99.82% +99.4%
Debt/Equity 3.53 +209.1%
Interest Coverage -4.15 +77.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.2x book value

✗Weaknesses

✗High debt to equity ratio of 3.5x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 13.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM2925.73%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-467.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-102.6%

ROCE

10Y Avg-120.68%

5Y Avg-62.66%

3Y Avg-62.71%

Latest-30.59%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.47B	291.93	97.31	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.6B	55.20	24.98	17.97%	16.82%	8.59%	4.48%	0.11
SRPTSarepta Therapeutics, Inc.	2.25B	21.46	9.17	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.33B	24.11	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.81B	17.04	-5.06			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.6B	29.11	-7.13	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.51B	34.55	-7.54	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.23B	41.51	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	3.5M	0	3M	0	0	0	2.56M
Revenue Growth %	-	-	-	-	-1%	-	-1%	-	-	-
Cost of Goods Sold+	400K	300K	195K	103K	672K	0	0	0	0	797K
COGS % of Revenue	-	-	-	0.03%	-	-	-	-	-	0.31%
Gross Profit+	-400K	-300K	-195K	3.4M	-672K	3M	0	0	0	1.76M
Gross Margin %	-	-	-	0.97%	-	1%	-	-	-	0.69%
Gross Profit Growth %	-	0.25%	0.35%	18.42%	-1.2%	5.46%	-1%	-	-	-
Operating Expenses+	12.67M	21.96M	32.27M	46.21M	47.8M	62.87M	85.11M	87.57M	107.52M	38.16M
OpEx % of Revenue	-	-	-	13.2%	-	20.96%	-	-	-	14.92%
Selling, General & Admin	2.12M	6.51M	8.01M	18.41M	17.64M	20.94M	24.7M	27.02M	35.51M	61.52M
SG&A % of Revenue	-	-	-	5.26%	-	6.98%	-	-	-	24.06%
Research & Development	12.71M	17.83M	28.13M	30.98M	30.16M	41.93M	50.65M	61.06M	72.02M	81.64M
R&D % of Revenue	-	-	-	8.85%	-	13.98%	-	-	-	31.93%
Other Operating Expenses	-77K	104K	-16K	-85K	0	0	9.76M	-509K	0	-105M
Operating Income+	-14.82M	-24.35M	-36.13M	-45.88M	-51.7M	-59.87M	-85.11M	-87.57M	-107.52M	-36.4M
Operating Margin %	-	-	-	-13.11%	-	-19.96%	-	-	-	-14.24%
Operating Income Growth %	-	-0.64%	-0.48%	-0.27%	-0.13%	-0.16%	-0.42%	-0.03%	-0.23%	0.66%
EBITDA+	-14.44M	-24.05M	-35.94M	-45.78M	-51.03M	-58.64M	-84.61M	-87.06M	-107.1M	-35.6M
EBITDA Margin %	-	-	-	-13.08%	-	-19.55%	-	-	-	-13.92%
EBITDA Growth %	-	-0.67%	-0.49%	-0.27%	-0.11%	-0.15%	-0.44%	-0.03%	-0.23%	0.67%
D&A (Non-Cash Add-back)	389K	300K	195K	103K	672K	1.23M	499K	513K	419K	796K
EBIT	-12.75M	-20.46M	-31.8M	-32.56M	-50.66M	-59.3M	-85.04M	-89.85M	-95.31M	-28.37M
Net Interest Income+	0	0	-1.86M	-230K	-950K	-2.42M	-3.63M	-3.77M	-1.2M	-3M
Interest Income	0	0	214K	809K	1.2M	273K	10K	219K	4.58M	5.77M
Interest Expense	472K	2.52M	2.08M	1.04M	2.15M	2.69M	3.64M	3.99M	5.78M	8.77M
Other Income/Expense	1.61M	6.48M	2.26M	2.86M	-1.1M	-2.11M	-3.57M	-6.27M	6.43M	-739K
Pretax Income+	-13.22M	-22.98M	-33.88M	-43.02M	-52.81M	-61.98M	-88.68M	-93.84M	-101.09M	-37.14M
Pretax Margin %	-	-	-	-12.29%	-	-20.66%	-	-	-	-14.52%
Income Tax+	0	2.62M	0	3.9M	0	148K	17K	28K	78K	310K
Effective Tax Rate %	1%	1%	1%	1%	1.07%	1%	1%	1%	1%	1.01%
Net Income+	-13.22M	-22.98M	-33.88M	-43.02M	-56.6M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Net Margin %	-	-	-	-12.29%	-	-20.71%	-	-	-	-14.65%
Net Income Growth %	-	-0.74%	-0.47%	-0.27%	-0.32%	-0.1%	-0.43%	-0.06%	-0.08%	0.63%
Net Income (Continuing)	-13.22M	-22.98M	-33.88M	-33.28M	-52.81M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1000.15	-1737.74	-1637.10	-2373.00	-138.90	-92.70	-119.70	-45.60	-17.10	-5.59
EPS Growth %	-	-0.74%	0.06%	-0.45%	0.94%	0.33%	-0.29%	0.62%	0.63%	0.67%
EPS (Basic)	-1000.15	-1737.74	-1637.10	-2373.00	-138.90	-92.70	-119.70	-45.60	-17.10	-5.59
Diluted Shares Outstanding	13.23K	13.23K	15.27K	15.3K	384.33K	669.23K	858.29K	2.12M	5.93M	6.7M
Basic Shares Outstanding	13.23K	13.23K	13.43K	14.03K	380.07K	669.23K	741.7K	2.06M	5.93M	6.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.39M	5.72M	80.83M	35.08M	129.28M	83.31M	87.88M	128.68M	122.08M	112.17M
Cash & Short-Term Investments	6.76M	3.04M	76.79M	30.75M	126.18M	78.71M	81.79M	121.72M	114.22M	102.06M
Cash Only	6.76M	3.04M	76.79M	30.75M	126.18M	78.71M	81.79M	121.72M	99.22M	55.7M
Short-Term Investments	0	0	0	0	0	0	0	0	15M	46.36M
Accounts Receivable	1.54M	1.34M	1.61M	2.86M	2M	917K	747K	1.15M	562K	1.71M
Days Sales Outstanding	-	-	-	298.15	-	111.57	-	-	-	244.09
Inventory	0	1.25M	355K	0	0	0	0	0	0	2.82M
Days Inventory Outstanding	-	1.52K	664.49	-	-	-	-	-	-	1.29K
Other Current Assets	0	0	0	101K	0	0	0	5.81M	7.3M	5.59M
Total Non-Current Assets+	1.12M	1.89M	421K	924K	31.42M	39.56M	29.3M	26.91M	25.18M	34.27M
Property, Plant & Equipment	760K	519K	421K	285K	2.36M	9.2M	10.22M	8.33M	6.39M	4.84M
Fixed Asset Turnover	-	-	-	12.28x	-	0.33x	-	-	-	0.53x
Goodwill	0	0	0	0	27.11M	27.11M	17.35M	17.35M	17.35M	17.35M
Intangible Assets	0	0	0	0	0	0	0	0	0	10M
Long-Term Investments	338K	394K	355K	364K	0	0	1.32M	1.02M	0	0
Other Non-Current Assets	25K	975K	-355K	275K	1.95M	3.26M	1.72M	1.23M	1.44M	2.08M
Total Assets+	9.51M	7.6M	81.25M	36M	160.7M	122.87M	117.18M	155.59M	147.26M	146.45M
Asset Turnover	-	-	-	0.10x	-	0.02x	-	-	-	0.02x
Asset Growth %	-	-0.2%	9.69%	-0.56%	3.46%	-0.24%	-0.05%	0.33%	-0.05%	-0.01%
Total Current Liabilities+	6.68M	12.06M	7.68M	5.4M	9.45M	11.95M	14.02M	22.32M	22.86M	32.88M
Accounts Payable	423K	1.65M	1.89M	545K	2.09M	3.14M	4.28M	7.78M	8.95M	8.62M
Days Payables Outstanding	385.99	2K	3.54K	1.93K	1.13K	-	-	-	-	3.95K
Short-Term Debt	2.49M	5.13M	2.31M	1.69M	0	0	795K	1.31M	0	0
Deferred Revenue (Current)	430K	504K	1000K	737K	0	0	0	0	0	0
Other Current Liabilities	2.39M	3.48M	3.33M	1.5M	2.92M	3.76M	5.42M	6.59M	8.2M	13.05M
Current Ratio	1.26x	0.47x	10.52x	6.50x	13.68x	6.97x	6.27x	5.76x	5.34x	3.41x
Quick Ratio	1.26x	0.37x	10.48x	6.50x	13.68x	6.97x	6.27x	5.76x	5.34x	3.33x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-2.41K
Total Non-Current Liabilities+	37.16M	52.11M	14.87M	9.01M	22.03M	38.12M	38.74M	59.21M	73.3M	91.42M
Long-Term Debt	4.7M	10.13M	9.92M	7.89M	20.1M	33.18M	33.14M	32.3M	54.57M	75.42M
Capital Lease Obligations	-29.95M	-39.84M	0	0	1.92M	4.48M	4.78M	3.6M	2.61M	1.41M
Deferred Tax Liabilities	29.95M	39.84M	-9K	0	0	0	0	0	0	0
Other Non-Current Liabilities	-29.88M	-39.75M	9K	5K	16K	462K	826K	23.3M	16.11M	14.59M
Total Liabilities	43.83M	64.17M	22.55M	14.4M	31.48M	50.07M	52.76M	81.53M	96.16M	124.3M
Total Debt+	7.19M	15.29M	12.24M	7.89M	22.91M	38.45M	39.78M	38.42M	58.28M	78.09M
Net Debt	435K	12.25M	-64.56M	-22.86M	-103.27M	-40.26M	-42M	-83.3M	-40.94M	22.39M
Debt / Equity	-	-	0.21x	0.37x	0.18x	0.53x	0.62x	0.52x	1.14x	3.53x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-31.41x	-9.68x	-17.38x	-44.16x	-24.08x	-22.27x	-23.37x	-21.93x	-18.61x	-4.15x
Total Equity+	-34.32M	-56.56M	58.71M	21.6M	129.22M	72.8M	64.41M	74.05M	51.1M	22.15M
Equity Growth %	-	-0.65%	2.04%	-0.63%	4.98%	-0.44%	-0.12%	0.15%	-0.31%	-0.57%
Book Value per Share	-2593.28	-4273.67	3845.44	1411.77	336.22	108.78	75.05	34.97	8.62	3.30
Total Shareholders' Equity	-34.32M	-56.56M	58.71M	21.6M	129.22M	72.8M	64.41M	74.05M	51.1M	22.15M
Common Stock	1K	1K	15K	15K	16K	16K	28K	122K	167K	171K
Retained Earnings	-35.41M	-58.39M	-92.27M	-135.29M	-132.04M	-194.18M	-282.87M	-376.74M	-477.9M	-515.36M
Treasury Stock	-371K	0	0	0	0	0	0	0	0	0
Accumulated OCI	718K	834K	127K	241K	-119K	-119K	-119K	-119K	-119K	-122K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.82M	-21.64M	-27.87M	-40.9M	-48.05M	-58.82M	-70.91M	-77.1M	-96.51M	-130.9M
Operating CF Margin %	-	-	-	-11.69%	-	-19.61%	-	-	-	-51.19%
Operating CF Growth %	-	-1%	-0.29%	-0.47%	-0.17%	-0.22%	-0.21%	-0.09%	-0.25%	-0.36%
Net Income	-13.22M	-22.98M	-33.88M	-43.02M	-52.81M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Depreciation & Amortization	389K	285K	195K	155K	103K	351K	499K	513K	419K	796K
Stock-Based Compensation	126K	644K	906K	5.62M	2.05M	5.43M	6.18M	5.2M	8.69M	8.2M
Deferred Taxes	-1K	-1.39M	-269K	0	-2.15M	-5.78M	-6.68M	0	0	0
Other Non-Cash Items	441K	2.32M	1.75M	804K	7.99M	7.38M	19.29M	5.32M	-4.79M	-105.13M
Working Capital Changes	1.45M	-517K	3.42M	-4.46M	-3.24M	-4.06M	-1.5M	5.74M	344K	2.67M
Change in Receivables	-56K	152K	-64K	-1.37M	0	0	0	-610K	0	-1.07M
Change in Inventory	0	0	0	0	0	0	0	610K	0	-2.82M
Change in Payables	77K	1.26M	182K	-1.34M	-2.75M	1.03M	1.17M	3.42M	1.23M	-286K
Cash from Investing+	-247K	-138K	34K	-34K	27.23M	-1.36M	-615K	-103K	-14.88M	66.99M
Capital Expenditures	-170K	-73K	-42K	-34K	-174K	-1.36M	-615K	-103K	-60K	-326K
CapEx % of Revenue	-	-	-	0.01%	-	0.45%	-	-	-	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-77K	-65K	76K	0	1M	0	0	4.8M	0	98M
Cash from Financing+	11.51M	18.15M	101.26M	-4.53M	140.66M	12.39M	74.25M	117.23M	88.52M	20.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	16K	-30K	-7.87M	7K	792K	284K	260K	-4.61M	8.08M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.99M	-21.71M	-27.91M	-40.94M	-48.23M	-60.18M	-71.52M	-77.2M	-96.57M	-131.23M
FCF Margin %	-	-	-	-11.7%	-	-20.06%	-	-	-	-51.32%
FCF Growth %	-	-0.98%	-0.29%	-0.47%	-0.18%	-0.25%	-0.19%	-0.08%	-0.25%	-0.36%
FCF per Share	-830.07	-1640.50	-1828.36	-2675.62	-125.49	-89.92	-83.33	-36.46	-16.29	-19.58
FCF Conversion (FCF/Net Income)	0.82x	0.94x	0.82x	0.95x	0.85x	0.95x	0.80x	0.82x	0.95x	3.50x
Interest Paid	81K	291K	0	0	0	0	0	0	0	0
Taxes Paid	29K	4K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-3158.69%	-107.14%	-75.06%	-61.51%	-129.28%	-135.58%	-161.67%	-102.26%
Return on Invested Capital (ROIC)	-	-	-	-	-314.13%	-153.55%	-232.33%	-997.9%	-17588.11%	-99.82%
Gross Margin	-	-	-	97.06%	-	100%	-	-	-	68.83%
Net Margin	-	-	-	-1229.17%	-	-2071.03%	-	-	-	-1464.61%
Debt / Equity	-	-	0.21x	0.37x	0.18x	0.53x	0.62x	0.52x	1.14x	3.53x
Interest Coverage	-31.41x	-9.68x	-17.38x	-44.16x	-24.08x	-22.27x	-23.37x	-21.93x	-18.61x	-4.15x
FCF Conversion	0.82x	0.94x	0.82x	0.95x	0.85x	0.95x	0.80x	0.82x	0.95x	3.50x
Revenue Growth	-	-	-	-	-100%	-	-100%	-	-	-

Revenue by Segment

	2024
Product Returns	11K
Product Returns Growth	-

Frequently Asked Questions

Growth & Financials

X4 Pharmaceuticals, Inc. (XFOR) reported $34.0M in revenue for fiscal year 2024.

X4 Pharmaceuticals, Inc. (XFOR) grew revenue by 0.0% over the past year. Growth has been modest.

X4 Pharmaceuticals, Inc. (XFOR) reported a net loss of $95.1M for fiscal year 2024.

Dividend & Returns

X4 Pharmaceuticals, Inc. (XFOR) has a return on equity (ROE) of -102.3%. Negative ROE indicates the company is unprofitable.

X4 Pharmaceuticals, Inc. (XFOR) had negative free cash flow of $106.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

X4 Pharmaceuticals, Inc. (XFOR) 10-Year Financial Performance & Capital Metrics

XFOR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $3M
EBITDA -$36M +66.8%
Net Income -$37M +63.0%
EPS (Diluted) -5.59 +67.3%
Gross Margin 68.83%
EBITDA Margin -1392.45%
Operating Margin -1423.58%
Net Margin -1464.61%
ROE -102.26% +36.8%
ROIC -99.82% +99.4%
Debt/Equity 3.53 +209.1%
Interest Coverage -4.15 +77.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 1.2x book value

✗Weaknesses

✗High debt to equity ratio of 3.5x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 13.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM2925.73%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-467.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-102.6%

ROCE

10Y Avg-120.68%

5Y Avg-62.66%

3Y Avg-62.71%

Latest-30.59%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.47B	291.93	97.31	473.02%	53.3%	17.48%	1.41%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.6B	55.20	24.98	17.97%	16.82%	8.59%	4.48%	0.11
SRPTSarepta Therapeutics, Inc.	2.25B	21.46	9.17	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.33B	24.11	-3.83	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.81B	17.04	-5.06			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.6B	29.11	-7.13	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.51B	34.55	-7.54	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.23B	41.51	-9.48		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	3.5M	0	3M	0	0	0	2.56M
Revenue Growth %	-	-	-	-	-1%	-	-1%	-	-	-
Cost of Goods Sold+	400K	300K	195K	103K	672K	0	0	0	0	797K
COGS % of Revenue	-	-	-	0.03%	-	-	-	-	-	0.31%
Gross Profit+	-400K	-300K	-195K	3.4M	-672K	3M	0	0	0	1.76M
Gross Margin %	-	-	-	0.97%	-	1%	-	-	-	0.69%
Gross Profit Growth %	-	0.25%	0.35%	18.42%	-1.2%	5.46%	-1%	-	-	-
Operating Expenses+	12.67M	21.96M	32.27M	46.21M	47.8M	62.87M	85.11M	87.57M	107.52M	38.16M
OpEx % of Revenue	-	-	-	13.2%	-	20.96%	-	-	-	14.92%
Selling, General & Admin	2.12M	6.51M	8.01M	18.41M	17.64M	20.94M	24.7M	27.02M	35.51M	61.52M
SG&A % of Revenue	-	-	-	5.26%	-	6.98%	-	-	-	24.06%
Research & Development	12.71M	17.83M	28.13M	30.98M	30.16M	41.93M	50.65M	61.06M	72.02M	81.64M
R&D % of Revenue	-	-	-	8.85%	-	13.98%	-	-	-	31.93%
Other Operating Expenses	-77K	104K	-16K	-85K	0	0	9.76M	-509K	0	-105M
Operating Income+	-14.82M	-24.35M	-36.13M	-45.88M	-51.7M	-59.87M	-85.11M	-87.57M	-107.52M	-36.4M
Operating Margin %	-	-	-	-13.11%	-	-19.96%	-	-	-	-14.24%
Operating Income Growth %	-	-0.64%	-0.48%	-0.27%	-0.13%	-0.16%	-0.42%	-0.03%	-0.23%	0.66%
EBITDA+	-14.44M	-24.05M	-35.94M	-45.78M	-51.03M	-58.64M	-84.61M	-87.06M	-107.1M	-35.6M
EBITDA Margin %	-	-	-	-13.08%	-	-19.55%	-	-	-	-13.92%
EBITDA Growth %	-	-0.67%	-0.49%	-0.27%	-0.11%	-0.15%	-0.44%	-0.03%	-0.23%	0.67%
D&A (Non-Cash Add-back)	389K	300K	195K	103K	672K	1.23M	499K	513K	419K	796K
EBIT	-12.75M	-20.46M	-31.8M	-32.56M	-50.66M	-59.3M	-85.04M	-89.85M	-95.31M	-28.37M
Net Interest Income+	0	0	-1.86M	-230K	-950K	-2.42M	-3.63M	-3.77M	-1.2M	-3M
Interest Income	0	0	214K	809K	1.2M	273K	10K	219K	4.58M	5.77M
Interest Expense	472K	2.52M	2.08M	1.04M	2.15M	2.69M	3.64M	3.99M	5.78M	8.77M
Other Income/Expense	1.61M	6.48M	2.26M	2.86M	-1.1M	-2.11M	-3.57M	-6.27M	6.43M	-739K
Pretax Income+	-13.22M	-22.98M	-33.88M	-43.02M	-52.81M	-61.98M	-88.68M	-93.84M	-101.09M	-37.14M
Pretax Margin %	-	-	-	-12.29%	-	-20.66%	-	-	-	-14.52%
Income Tax+	0	2.62M	0	3.9M	0	148K	17K	28K	78K	310K
Effective Tax Rate %	1%	1%	1%	1%	1.07%	1%	1%	1%	1%	1.01%
Net Income+	-13.22M	-22.98M	-33.88M	-43.02M	-56.6M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Net Margin %	-	-	-	-12.29%	-	-20.71%	-	-	-	-14.65%
Net Income Growth %	-	-0.74%	-0.47%	-0.27%	-0.32%	-0.1%	-0.43%	-0.06%	-0.08%	0.63%
Net Income (Continuing)	-13.22M	-22.98M	-33.88M	-33.28M	-52.81M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1000.15	-1737.74	-1637.10	-2373.00	-138.90	-92.70	-119.70	-45.60	-17.10	-5.59
EPS Growth %	-	-0.74%	0.06%	-0.45%	0.94%	0.33%	-0.29%	0.62%	0.63%	0.67%
EPS (Basic)	-1000.15	-1737.74	-1637.10	-2373.00	-138.90	-92.70	-119.70	-45.60	-17.10	-5.59
Diluted Shares Outstanding	13.23K	13.23K	15.27K	15.3K	384.33K	669.23K	858.29K	2.12M	5.93M	6.7M
Basic Shares Outstanding	13.23K	13.23K	13.43K	14.03K	380.07K	669.23K	741.7K	2.06M	5.93M	6.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.39M	5.72M	80.83M	35.08M	129.28M	83.31M	87.88M	128.68M	122.08M	112.17M
Cash & Short-Term Investments	6.76M	3.04M	76.79M	30.75M	126.18M	78.71M	81.79M	121.72M	114.22M	102.06M
Cash Only	6.76M	3.04M	76.79M	30.75M	126.18M	78.71M	81.79M	121.72M	99.22M	55.7M
Short-Term Investments	0	0	0	0	0	0	0	0	15M	46.36M
Accounts Receivable	1.54M	1.34M	1.61M	2.86M	2M	917K	747K	1.15M	562K	1.71M
Days Sales Outstanding	-	-	-	298.15	-	111.57	-	-	-	244.09
Inventory	0	1.25M	355K	0	0	0	0	0	0	2.82M
Days Inventory Outstanding	-	1.52K	664.49	-	-	-	-	-	-	1.29K
Other Current Assets	0	0	0	101K	0	0	0	5.81M	7.3M	5.59M
Total Non-Current Assets+	1.12M	1.89M	421K	924K	31.42M	39.56M	29.3M	26.91M	25.18M	34.27M
Property, Plant & Equipment	760K	519K	421K	285K	2.36M	9.2M	10.22M	8.33M	6.39M	4.84M
Fixed Asset Turnover	-	-	-	12.28x	-	0.33x	-	-	-	0.53x
Goodwill	0	0	0	0	27.11M	27.11M	17.35M	17.35M	17.35M	17.35M
Intangible Assets	0	0	0	0	0	0	0	0	0	10M
Long-Term Investments	338K	394K	355K	364K	0	0	1.32M	1.02M	0	0
Other Non-Current Assets	25K	975K	-355K	275K	1.95M	3.26M	1.72M	1.23M	1.44M	2.08M
Total Assets+	9.51M	7.6M	81.25M	36M	160.7M	122.87M	117.18M	155.59M	147.26M	146.45M
Asset Turnover	-	-	-	0.10x	-	0.02x	-	-	-	0.02x
Asset Growth %	-	-0.2%	9.69%	-0.56%	3.46%	-0.24%	-0.05%	0.33%	-0.05%	-0.01%
Total Current Liabilities+	6.68M	12.06M	7.68M	5.4M	9.45M	11.95M	14.02M	22.32M	22.86M	32.88M
Accounts Payable	423K	1.65M	1.89M	545K	2.09M	3.14M	4.28M	7.78M	8.95M	8.62M
Days Payables Outstanding	385.99	2K	3.54K	1.93K	1.13K	-	-	-	-	3.95K
Short-Term Debt	2.49M	5.13M	2.31M	1.69M	0	0	795K	1.31M	0	0
Deferred Revenue (Current)	430K	504K	1000K	737K	0	0	0	0	0	0
Other Current Liabilities	2.39M	3.48M	3.33M	1.5M	2.92M	3.76M	5.42M	6.59M	8.2M	13.05M
Current Ratio	1.26x	0.47x	10.52x	6.50x	13.68x	6.97x	6.27x	5.76x	5.34x	3.41x
Quick Ratio	1.26x	0.37x	10.48x	6.50x	13.68x	6.97x	6.27x	5.76x	5.34x	3.33x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-2.41K
Total Non-Current Liabilities+	37.16M	52.11M	14.87M	9.01M	22.03M	38.12M	38.74M	59.21M	73.3M	91.42M
Long-Term Debt	4.7M	10.13M	9.92M	7.89M	20.1M	33.18M	33.14M	32.3M	54.57M	75.42M
Capital Lease Obligations	-29.95M	-39.84M	0	0	1.92M	4.48M	4.78M	3.6M	2.61M	1.41M
Deferred Tax Liabilities	29.95M	39.84M	-9K	0	0	0	0	0	0	0
Other Non-Current Liabilities	-29.88M	-39.75M	9K	5K	16K	462K	826K	23.3M	16.11M	14.59M
Total Liabilities	43.83M	64.17M	22.55M	14.4M	31.48M	50.07M	52.76M	81.53M	96.16M	124.3M
Total Debt+	7.19M	15.29M	12.24M	7.89M	22.91M	38.45M	39.78M	38.42M	58.28M	78.09M
Net Debt	435K	12.25M	-64.56M	-22.86M	-103.27M	-40.26M	-42M	-83.3M	-40.94M	22.39M
Debt / Equity	-	-	0.21x	0.37x	0.18x	0.53x	0.62x	0.52x	1.14x	3.53x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-31.41x	-9.68x	-17.38x	-44.16x	-24.08x	-22.27x	-23.37x	-21.93x	-18.61x	-4.15x
Total Equity+	-34.32M	-56.56M	58.71M	21.6M	129.22M	72.8M	64.41M	74.05M	51.1M	22.15M
Equity Growth %	-	-0.65%	2.04%	-0.63%	4.98%	-0.44%	-0.12%	0.15%	-0.31%	-0.57%
Book Value per Share	-2593.28	-4273.67	3845.44	1411.77	336.22	108.78	75.05	34.97	8.62	3.30
Total Shareholders' Equity	-34.32M	-56.56M	58.71M	21.6M	129.22M	72.8M	64.41M	74.05M	51.1M	22.15M
Common Stock	1K	1K	15K	15K	16K	16K	28K	122K	167K	171K
Retained Earnings	-35.41M	-58.39M	-92.27M	-135.29M	-132.04M	-194.18M	-282.87M	-376.74M	-477.9M	-515.36M
Treasury Stock	-371K	0	0	0	0	0	0	0	0	0
Accumulated OCI	718K	834K	127K	241K	-119K	-119K	-119K	-119K	-119K	-122K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.82M	-21.64M	-27.87M	-40.9M	-48.05M	-58.82M	-70.91M	-77.1M	-96.51M	-130.9M
Operating CF Margin %	-	-	-	-11.69%	-	-19.61%	-	-	-	-51.19%
Operating CF Growth %	-	-1%	-0.29%	-0.47%	-0.17%	-0.22%	-0.21%	-0.09%	-0.25%	-0.36%
Net Income	-13.22M	-22.98M	-33.88M	-43.02M	-52.81M	-62.13M	-88.7M	-93.87M	-101.17M	-37.45M
Depreciation & Amortization	389K	285K	195K	155K	103K	351K	499K	513K	419K	796K
Stock-Based Compensation	126K	644K	906K	5.62M	2.05M	5.43M	6.18M	5.2M	8.69M	8.2M
Deferred Taxes	-1K	-1.39M	-269K	0	-2.15M	-5.78M	-6.68M	0	0	0
Other Non-Cash Items	441K	2.32M	1.75M	804K	7.99M	7.38M	19.29M	5.32M	-4.79M	-105.13M
Working Capital Changes	1.45M	-517K	3.42M	-4.46M	-3.24M	-4.06M	-1.5M	5.74M	344K	2.67M
Change in Receivables	-56K	152K	-64K	-1.37M	0	0	0	-610K	0	-1.07M
Change in Inventory	0	0	0	0	0	0	0	610K	0	-2.82M
Change in Payables	77K	1.26M	182K	-1.34M	-2.75M	1.03M	1.17M	3.42M	1.23M	-286K
Cash from Investing+	-247K	-138K	34K	-34K	27.23M	-1.36M	-615K	-103K	-14.88M	66.99M
Capital Expenditures	-170K	-73K	-42K	-34K	-174K	-1.36M	-615K	-103K	-60K	-326K
CapEx % of Revenue	-	-	-	0.01%	-	0.45%	-	-	-	0.13%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-77K	-65K	76K	0	1M	0	0	4.8M	0	98M
Cash from Financing+	11.51M	18.15M	101.26M	-4.53M	140.66M	12.39M	74.25M	117.23M	88.52M	20.29M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	16K	-30K	-7.87M	7K	792K	284K	260K	-4.61M	8.08M	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.99M	-21.71M	-27.91M	-40.94M	-48.23M	-60.18M	-71.52M	-77.2M	-96.57M	-131.23M
FCF Margin %	-	-	-	-11.7%	-	-20.06%	-	-	-	-51.32%
FCF Growth %	-	-0.98%	-0.29%	-0.47%	-0.18%	-0.25%	-0.19%	-0.08%	-0.25%	-0.36%
FCF per Share	-830.07	-1640.50	-1828.36	-2675.62	-125.49	-89.92	-83.33	-36.46	-16.29	-19.58
FCF Conversion (FCF/Net Income)	0.82x	0.94x	0.82x	0.95x	0.85x	0.95x	0.80x	0.82x	0.95x	3.50x
Interest Paid	81K	291K	0	0	0	0	0	0	0	0
Taxes Paid	29K	4K	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-3158.69%	-107.14%	-75.06%	-61.51%	-129.28%	-135.58%	-161.67%	-102.26%
Return on Invested Capital (ROIC)	-	-	-	-	-314.13%	-153.55%	-232.33%	-997.9%	-17588.11%	-99.82%
Gross Margin	-	-	-	97.06%	-	100%	-	-	-	68.83%
Net Margin	-	-	-	-1229.17%	-	-2071.03%	-	-	-	-1464.61%
Debt / Equity	-	-	0.21x	0.37x	0.18x	0.53x	0.62x	0.52x	1.14x	3.53x
Interest Coverage	-31.41x	-9.68x	-17.38x	-44.16x	-24.08x	-22.27x	-23.37x	-21.93x	-18.61x	-4.15x
FCF Conversion	0.82x	0.94x	0.82x	0.95x	0.85x	0.95x	0.80x	0.82x	0.95x	3.50x
Revenue Growth	-	-	-	-	-100%	-	-100%	-	-	-

Revenue by Segment

	2024
Product Returns	11K
Product Returns Growth	-

Frequently Asked Questions

Growth & Financials

X4 Pharmaceuticals, Inc. (XFOR) reported $34.0M in revenue for fiscal year 2024.

X4 Pharmaceuticals, Inc. (XFOR) grew revenue by 0.0% over the past year. Growth has been modest.

X4 Pharmaceuticals, Inc. (XFOR) reported a net loss of $95.1M for fiscal year 2024.

Dividend & Returns

X4 Pharmaceuticals, Inc. (XFOR) has a return on equity (ROE) of -102.3%. Negative ROE indicates the company is unprofitable.

X4 Pharmaceuticals, Inc. (XFOR) had negative free cash flow of $106.1M in fiscal year 2024, likely due to heavy capital investments.